0.92
-0.05(-5.15%)
Currency In USD
| Previous Close | 0.97 |
| Open | 0.94 |
| Day High | 0.94 |
| Day Low | 0.87 |
| 52-Week High | 3.85 |
| 52-Week Low | 0.28 |
| Volume | 284,285 |
| Average Volume | 7.14M |
| Market Cap | 6.85M |
| PE | -0.21 |
| EPS | -4.43 |
| Moving Average 50 Days | 0.94 |
| Moving Average 200 Days | 0.91 |
| Change | -0.05 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $12.92 as of January 08, 2026 at a share price of $0.92. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $76.67 as of January 08, 2026 at a share price of $0.92.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Ma
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
GlobeNewswire Inc.
Nov 28, 2025 2:20 PM GMT
Extends cash runway through at least the first half of 2028Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management MIAMI, Nov. 28, 2025 (GLOBE NE
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage biomarker-driven clinical trials of novel or repurposed t